Janssen files patent infringement trial against Samsung Bioepis

Janssen, a U.S. global pharmaceutical company, filed a patent infringement trial against Samsung Bioepis.

Janssen recently sued Samsung Bioepis for infringing the 3 patents of ‘Remicade’ with the company’s ‘Renflexis’ at the Superior Court of New Jersey.

‘Renflexis,’ a Samsung Bioepis’s autoimmune therapy, is a biosimilar referencing ‘Remicade,’ a pharmaceutical product developed by Janssen.